
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AccuTOX,Nivolumab,Relatlimab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Defence’s Succesfull Accutoxtm Pre-Clinical Efficacy Study Complete Ready for Phase I IND Filing
Details : AccuTOX with anti-PD-1 and anti-LAG3 has shown to be very efficient at impeding tumor growth in many animal models including T-cell lymphoma, breast cancer and melanoma.
Product Name : AccuTOX
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 02, 2023
Lead Product(s) : AccuTOX,Nivolumab,Relatlimab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
